Table 3 Comparison between alterations in biochemical parameters in intervention and control group
| Â | Intervention group | Placebo group | Difference intervention group (absolute value and %) | Difference placebo group (absolute value and %) | 95% CI of difference | p-value | ||
|---|---|---|---|---|---|---|---|---|
Baseline intervention | Baseline intervention | |||||||
LDL (SD) mg/dL | 164.3 (32.2) | 122.6 (19.8) | 170.7 (40.9) | 171.5 (41.8) | −41.7 (−23.7%) (28.3) | 0.8 (0.5%) (24.3) | 25.9; 56.0 | <0.001 |
total CHOL (SD) mg/dL | 247.5 (38.1) | 204.0 (26.0) | 251.2 (39.2) | 255.1 (50.0) | −43.5 (−16.5%) (31.1) | 4.0 (2.0%) (23.7) | 31.6; 63.3 | <0.001 |
HDL (SD) mg/dL | 56.3 (14.3) | 58.0 (13.8) | 53.5 (13.9) | 54.3 (14.0) | 1.6 (3.5%) (4.3) | 0.8 (2.4%) (7.7) | −4.3; 2.7 | 0.64 |
TG (SD) mg/dL | 134.5 (57.9) | 117.5 (53.9) | 132.7 (49.5) | 150.3 (84.4) | −16.1 (−8.7%) (37.4) | 19.3 (15.9%) (64.6) | 5.7; 65.1 | 0.02 |
apoA (SD) mg/dL | 162.2 (39.5) | 171.2 (5.8) | 157.3 (30.6) | 161.1 (31.0) | 4.7 (2.9%) (9.4) | 3.9 (3.1%) (18.8) | −18.5; 8.2 | 0.44 |
apoB (SD) mg/dL | 115.5 (25.1) | 96.6 (16.5) | 119.3 (22.1) | 126.3 (5.4) | −19.0 (−14.7%) (18.3) | 7.0 (6.0%) (14.1) | 16.6; 35.5 | <0.001 |
HbA1c (SD) mmol/mol | 35.3 (3.2) | 36.1 (2.6) | 35.9 (6.4) | 36.7 (6.5) | 0.9 (2.9%) (1.6) | 0.7 (2.0%) (1.6) | −0.7; 1.1 | 0.61 |
oxLDL (SD) U/L | 80.8 (34.5) | 61.5 (21.4) | 69.1 (17.7) | 72.8 (22.2) | −19.4 (−20.4%) (21.7) | 3.7 (5.2%) (11.3) | −35.2; −15.8 | <0.001 |